Reference
Fang S-C, et al. Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. OncoTargets and Therapy 10: 447-452, 18 Jan 2017. Available from: URL: http://doi.org/10.2147/OTT.S126613 - China
Rights and permissions
About this article
Cite this article
Apatinib. Reactions Weekly 1645, 40 (2017). https://doi.org/10.1007/s40278-017-28122-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-28122-1